Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study.
cardiac invasion
hepatic arterial infusion chemoembolization
oncologic emergency
sorafenib
tumor thrombus
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
02
07
2021
received:
11
02
2021
accepted:
29
07
2021
pubmed:
26
8
2021
medline:
9
8
2022
entrez:
25
8
2021
Statut:
ppublish
Résumé
Invasion beyond inferior vena cava (IVC) to right atrium (RA) is a rare complication in patients with advanced hepatocellular carcinoma (HCC), and results in fatal oncologic emergencies, including pulmonary embolism and right heart failure. As there is no gold standard treatment for unresectable HCC with tumor thrombi involving IVC and RA, we considered it valuable to assess safety and efficacy of a combination of hepatic arterial infusion chemoembolization (HAIC) therapy and external-beam radiation therapy (EBRT). The "New FP" was chosen as the HAIC therapy, in which the enhanced permeation and retention effect was achieved using a cisplatin-Lipiodol suspension combined with continuous infusion of 5-fluorouracil (5-FU). Sixteen patients with HCC with tumor thrombi in IVC, RA, and pulmonary arteries were enrolled. modified response evaluation criteria in solid tumors-based evaluation of response to the combination treatment was as follows: complete response, 6.2% (1 patient); partial response, 81.3% (13 patients); stable disease, 12.5% (2 patients); progressive disease, 0%. The median overall survival time (MST) was 19.0 months. Notably, MST of patients receiving sequential sorafenib monotherapy (39.0 months) was significantly longer than that of the rest (15.3 months). The combination of New FP and EBRT is an efficacious treatment option for unresectable HCC involving IVC and RA, complicated with pulmonary embolism. Sequential administration of molecular-targeted drugs may prolong survival in such patients.
Sections du résumé
BACKGROUND
Invasion beyond inferior vena cava (IVC) to right atrium (RA) is a rare complication in patients with advanced hepatocellular carcinoma (HCC), and results in fatal oncologic emergencies, including pulmonary embolism and right heart failure.
AIM
As there is no gold standard treatment for unresectable HCC with tumor thrombi involving IVC and RA, we considered it valuable to assess safety and efficacy of a combination of hepatic arterial infusion chemoembolization (HAIC) therapy and external-beam radiation therapy (EBRT).
METHODS AND RESULTS
The "New FP" was chosen as the HAIC therapy, in which the enhanced permeation and retention effect was achieved using a cisplatin-Lipiodol suspension combined with continuous infusion of 5-fluorouracil (5-FU). Sixteen patients with HCC with tumor thrombi in IVC, RA, and pulmonary arteries were enrolled. modified response evaluation criteria in solid tumors-based evaluation of response to the combination treatment was as follows: complete response, 6.2% (1 patient); partial response, 81.3% (13 patients); stable disease, 12.5% (2 patients); progressive disease, 0%. The median overall survival time (MST) was 19.0 months. Notably, MST of patients receiving sequential sorafenib monotherapy (39.0 months) was significantly longer than that of the rest (15.3 months).
CONCLUSION
The combination of New FP and EBRT is an efficacious treatment option for unresectable HCC involving IVC and RA, complicated with pulmonary embolism. Sequential administration of molecular-targeted drugs may prolong survival in such patients.
Identifiants
pubmed: 34431232
doi: 10.1002/cnr2.1539
pmc: PMC9351667
doi:
Substances chimiques
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1539Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Aliment Pharmacol Ther. 2010 Aug;32(4):543-50
pubmed: 20500734
Case Rep Oncol. 2017 Jan 6;10(1):8-14
pubmed: 28413389
Surg Today. 2018 Sep;48(9):819-824
pubmed: 29279997
Ann Surg Oncol. 2013 Mar;20(3):914-22
pubmed: 22956071
J Cancer Res Ther. 2019;15(2):305-311
pubmed: 30964102
Mol Clin Oncol. 2017 Dec;7(6):1013-1020
pubmed: 29285366
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Cancer Chemother Pharmacol. 2016 Feb;77(2):243-50
pubmed: 26754678
Mol Clin Oncol. 2017 Jan;6(1):111-114
pubmed: 28123741
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Cancer Rep (Hoboken). 2022 Aug;5(8):e1539
pubmed: 34431232
J Cancer Res Clin Oncol. 1998;124(7):397-400
pubmed: 9719503
Clin J Gastroenterol. 2015 Oct;8(5):300-5
pubmed: 26249525
Int J Radiat Biol. 2020 Jun;96(6):759-766
pubmed: 31977276
J Hepatol. 2001 Sep;35(3):421-30
pubmed: 11592607
Lancet Oncol. 2020 Jun;21(6):808-820
pubmed: 32502443
Cancer Imaging. 2015 May 26;15:7
pubmed: 26007646